Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity.

The trailing-twelve-month return on equity at Akorn (NASDAQ: AKRX) is 20.78%. Akorn's revenue for the same period is $304.28 million.

The trailing-twelve-month return on equity at Salix Pharmaceuticals (NASDAQ: SLXP) is 17.90%. Salix Pharma's operating margin for the same period is 26.47%.

The trailing-twelve-month return on equity at Mylan (NASDAQ: MYL) is 17.73%. Mylan's EPS for the same period is $1.52.

The trailing-twelve-month return on equity at Sagent Pharmaceuticals (NASDAQ: SGNT) is 16.09%. Sagent Pharma's profit margin for the same period is 12.09%.